blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2049132

EP2049132 - NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.10.2013
Database last updated on 19.10.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
DSM IP Assets B.V.
Het Overloon 1
6411 TE Heerlen / NL
[2012/49]
Former [2009/38]For all designated states
DSM IP Assets B.V.
Het Overloon 1
6411 TE Heerlen / NL
Former [2009/17]For all designated states
DSM IP Assets B.V.
Het Overloon 1
6411 TE Heerlen / NL
Inventor(s)01 / FOWLER, Ann
Marktgasse 8C
4310 Rheinfelden / CH
02 / GORALCZYK, Regina
Allmendweg 7
79639 Grenzach-Wyhlen / DE
03 / KILPERT, Claus
Eschenhof 5
68305 Mannheim / DE
04 / SCHUELER, Goede
Märkter Strasse 9
79591 Eimeldingen / DE
 [2009/23]
Former [2009/17]01 / FOWLER, Ann
Marktgasse 61
CH-4310 Rheinfelden / CH
02 / GORALCZYK, Regina
Allmendweg 7
79639 Grenzach-Wyhlen / DE
03 / KILPERT, Claus
Eschenhof 5
68305 Mannheim / DE
04 / SCHUELER, Goede
Märkter Strasse 9
79591 Eimeldingen / DE
Representative(s)Schwander, Kuno, et al
DSM Nutritional Products Ltd
Patent Department
Wurmisweg 576
4303 Kaiseraugst / CH
[2012/29]
Former [2009/17]Schwander, Kuno, et al
DSM Nutritional Products Ltd., Wurmisweg 576
4303 Kaiseraugst / CH
Application number, filing date07801575.709.08.2007
[2009/17]
WO2007EP07053
Priority number, dateEP2006001665909.08.2006         Original published format: EP 06016659
[2009/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008017484
Date:14.02.2008
Language:EN
[2008/07]
Type: A1 Application with search report 
No.:EP2049132
Date:22.04.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 14.02.2008 takes the place of the publication of the European patent application.
[2009/17]
Type: B1 Patent specification 
No.:EP2049132
Date:05.12.2012
Language:EN
[2012/49]
Search report(s)International search report - published on:EP14.02.2008
ClassificationIPC:A61K36/53, A61P25/24
[2009/17]
CPC:
A61K36/53 (EP,KR,US); A23K10/30 (EP,US); A23K50/40 (EP,US);
A23K50/50 (EP,US); A23L2/52 (EP,US); A23L33/105 (EP,US);
A23L7/126 (EP,US); A61K31/05 (EP,US); A61K31/122 (EP,US);
A61P1/00 (EP); A61P1/08 (EP); A61P17/04 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/06 (EP);
A61P25/14 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P29/00 (EP); A61P3/00 (EP); A61P3/04 (EP);
A61P43/00 (EP); A23V2002/00 (EP,US) (-)
C-Set:
A61K31/05, A61K2300/00 (EP,US);
A61K31/122, A61K2300/00 (US,EP);
A23V2002/00, A23V2200/322, A23V2250/21 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/17]
TitleGerman:NEUE WIRKSTOFFE ZUR BEHANDLUNG VON ERKRANKUNGEN IN ZUSAMMENHANG MIT GESTÖRTER NEUROTRANSMISSION[2009/17]
English:NOVEL AGENTS FOR THE TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION[2009/17]
French:NOUVEAUX AGENTS POUR LE TRAITEMENT DE TROUBLES EN RAPPORT AVEC UNE TRANSMISSION NERVEUSE ENDOMMAGÉE[2009/17]
Entry into regional phase16.01.2009National basic fee paid 
16.01.2009Designation fee(s) paid 
16.01.2009Examination fee paid 
Examination procedure16.01.2009Examination requested  [2009/17]
02.12.2009Despatch of a communication from the examining division (Time limit: M06)
07.04.2010Reply to a communication from the examining division
09.11.2010Despatch of a communication from the examining division (Time limit: M04)
25.02.2011Reply to a communication from the examining division
22.09.2011Despatch of a communication from the examining division (Time limit: M04)
16.01.2012Reply to a communication from the examining division
17.08.2012Communication of intention to grant the patent
24.10.2012Fee for grant paid
24.10.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.12.2009
Opposition(s)06.09.2013No opposition filed within time limit [2013/46]
Fees paidRenewal fee
25.08.2009Renewal fee patent year 03
25.08.2010Renewal fee patent year 04
25.08.2011Renewal fee patent year 05
10.08.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.08.2007
AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
DK05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
MC05.12.2012
MT05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
IE09.08.2013
LU09.08.2013
CH31.08.2013
LI31.08.2013
[2015/34]
Former [2015/32]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
DK05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
MC05.12.2012
MT05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
IE09.08.2013
CH31.08.2013
LI31.08.2013
Former [2014/33]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
DK05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
MC05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
IE09.08.2013
CH31.08.2013
LI31.08.2013
Former [2014/20]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
DK05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
MC05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
CH31.08.2013
LI31.08.2013
Former [2013/48]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
DK05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
Former [2013/40]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
PT05.04.2013
Former [2013/37]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
NL05.12.2012
RO05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
Former [2013/35]AT05.12.2012
BE05.12.2012
CY05.12.2012
CZ05.12.2012
EE05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
SI05.12.2012
SK05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
Former [2013/34]AT05.12.2012
BE05.12.2012
CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
SI05.12.2012
BG05.03.2013
GR06.03.2013
IS05.04.2013
Former [2013/33]AT05.12.2012
BE05.12.2012
CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
SI05.12.2012
GR06.03.2013
Former [2013/31]AT05.12.2012
CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
SI05.12.2012
GR06.03.2013
Former [2013/26]CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
SI05.12.2012
GR06.03.2013
Former [2013/24]CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
GR06.03.2013
Former [2013/23]CY05.12.2012
FI05.12.2012
LT05.12.2012
LV05.12.2012
SE05.12.2012
Former [2013/22]FI05.12.2012
LT05.12.2012
SE05.12.2012
Former [2013/21]LT05.12.2012
SE05.12.2012
Former [2013/20]LT05.12.2012
Cited inInternational search[X]WO0145780  (FENYO MARTA [HU]) [X] 1-14 *cf. table on page 13 bridging with page 14, claims 1, 5 and 6*;
 [Y]WO2006022616  (ALLTECH INC [US], et al) [Y] 1-14 *cf. page 3, lines 8-21, "summary of the invention, example 1, lines 10-16, claim 1*;
 [Y]RU2174005  ;
 [Y]RU2019185  ;
 [Y]RO115120  ;
 [Y]JP2006008555
 [Y]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2001, no. 75, Database accession no. 2001-655977, XP002416197 & RU2174005 C1 20010927 (FITO-EM AGRIC IND FIRM STOCK CO) [Y] 1-14 * abstract *
 [Y]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 1995, no. 21, Database accession no. 1995-159708, XP002416198 & RU2019185 C1 19940915 (RUSANOV S E) [Y] 1-14 * abstract *
 [Y]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2000, no. 22, Database accession no. 2000-254738, XP002416199 & RO115120 B1 19991130 (BOJOR O) [Y] 1-14 * abstract *
 [Y]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2006, no. 09, Database accession no. 2006-082996, XP002416200 & JP2006008555 A 20060112 (DOKURITSU GYOSEI HOJIN KAGAKU GIJUTSU SH) [Y] 1-14 * abstract *
by applicantWO9505838
 WO0145780
    - Neurotransmitters, Drugs and Brain function, JOHN WILEY & SONS, (2001), pages 187 - 211,289-
    - WIT- TCHEN ET AL., EUR. NEUROPSYCHOPHARM., (2005), vol. 15, pages 357 - 376
    - STOCCHI ET AL., J CLIN PSYCHIATRY, (2003), vol. 63, no. 3, page 250
    - FRANKLE ET AL., AM. J. PSYCH, (2005), vol. 162, pages 915 - 923
    - MARSH ET AL., NEUROPSYCHOPHARM, (2002), vol. 26, pages 660 - 671
    - GREYDANUS, IND. J. PED., (2005), vol. 72, pages 953 - 960
    - CHOUINARD, J. PSYCH. & NEURO., (2005), vol. 31, no. 3, pages 168 - 176
    - VOGEL ET AL., NEUROSCI BIOBEHAV REV, (1990), vol. 14, pages 49 - 63
    - MC CARLEY, AM JPSYCH., (1982), vol. 139, pages 565 - 570
    - SRANER ET AL., Clinical Pharmacology of Sleep, BIRKHäUSER, (2006), pages 103 - 124
    - CRAIG ET AL., AM. FAM. PHYSICIAN, (2002), vol. 65, pages 1083 - 1090
    - IRWIN S., PSYCHOPHARMA., (1968), vol. 13, pages 222 - 257
    - NAGATSU, NEUROTOX., (2004), vol. 25, pages 11 - 20
    - PORSOLT ET AL., ARCH. INT. PHARMACODYN, (1977), vol. 229, pages 327 - 336
    - WILKIE ET AL., J. EXP. ANAL.BEHAVIOR, (1979), vol. 31, pages 299 - 306
    - PINEL ET AL., J. COMP.PHYSIOL. PSYCH., (1978), vol. 92, pages 708 - 712
    - POLING ET AL., J. EXP. ANAL. BEHAVIOR, (1981), vol. 35, pages 31 - 44
    - BROEKKAMP ET AL., EUR J PHARMACOL., (1986), vol. 126, pages 223 - 229
    - DE BOER ET AL., EUR. J. PHARMA, (2003), vol. 463, pages 145 - 161
    - CRAWLEY, PHARMACOL. BIOCHEM. BEHAV., (1981), vol. 15, pages 695 - 699
    - GIROS ET AL., MOL. PHARMACOL., (1992), vol. 42, pages 383 - 390
    - PRISTUPA ET AL., MOL. PHARMACOL., (1994), vol. 45, pages 125 - 135
    - GALLI ET AL., J. EXP. BIOL., (1995), vol. 198, pages 2197 - 2212
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.